Active monitoring improves radiopharmaceutical administration quality
In 2016, our center adopted technology to routinely monitor F-FDG radiopharmaceutical administrations. Within six months of following basic quality improvement methodology, our technologists reduced extravasation rates from 13.3% to 2.9% (
Gespeichert in:
| Veröffentlicht in: | Frontiers in nuclear medicine 2023-03, Vol.3, p.1126029 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 1126029 |
| container_title | Frontiers in nuclear medicine |
| container_volume | 3 |
| creator | Crowley, James R Barvi, Iryna Kiser, Jackson W |
| description | In 2016, our center adopted technology to routinely monitor
F-FDG radiopharmaceutical administrations. Within six months of following basic quality improvement methodology, our technologists reduced extravasation rates from 13.3% to 2.9% (
|
| doi_str_mv | 10.3389/fnume.2023.1126029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11440977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3112116959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-a8c54160fc4c03b9a7acd501c4e9f2dcea52777a4a7cb1db9cc991612e9cae3b3</originalsourceid><addsrcrecordid>eNpVUctqwzAQFKWlCWl-oIfiYy9O9bJlnUoI6QMCvbRnsZblRMW2HMkO5O_rNGlIT7vLzswuMwjdEzxjLJNPZdPXZkYxZTNCaIqpvEJjmgoWZ1mGry_6EZqG8I0xpiLjFPNbNGKSJckwj9Fyrju7M1HtGts5b5t1ZOvWu50JkYfCunYDvgZt-s5qqCIoatvY0HnorGuibQ-V7fZ36KaEKpjpqU7Q18vyc_EWrz5e3xfzVaw5Zl0MmU44SXGpucYslyBAFwkmmhtZ0kIbSKgQAjgInZMil1pLSVJCjdRgWM4m6Pmo2_Z5bQZCMzxSqdbbGvxeObDq_6axG7V2O0UI51gKMSg8nhS82_YmdKq2QZuqgsa4Pig2mElIKhM5QOkRqr0LwZvyfIdgdchA_WagDhmoUwYD6eHywzPlz3H2A30FhuY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3112116959</pqid></control><display><type>article</type><title>Active monitoring improves radiopharmaceutical administration quality</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Crowley, James R ; Barvi, Iryna ; Kiser, Jackson W</creator><creatorcontrib>Crowley, James R ; Barvi, Iryna ; Kiser, Jackson W</creatorcontrib><description>In 2016, our center adopted technology to routinely monitor
F-FDG radiopharmaceutical administrations. Within six months of following basic quality improvement methodology, our technologists reduced extravasation rates from 13.3% to 2.9% (
< 0.0001). These same technologists administer other radiopharmaceuticals (without monitoring technology) for general nuclear medicine procedures in a separate facility at the clinic. Our hypothesis was that they would apply
F-FDG lessons-learned to
Tc-MDP administrations and that
Tc-MDP manual injection extravasation rate would be consistent with the ongoing
F-FDG manual injection extravasation rate (3.4%). We tested our hypothesis by following the same quality improvement methodology and added monitoring equipment to measure extravasation rates for
Tc-MDP administrations.
816
Tc-MDP administrations were monitored during 16-month period (four 4-month periods: A, B, C, D). Period A (first four months of active monitoring) extravasation rate was not statistically different from the Measure Phase extravasation rate of the previously completed PET/CT QI Project: 12.75% compared to 13.3% (
-0.7925). Period A extravasation rate was statistically different from Period C (months 9-12) extravasation rate and Period D (months 13-16) extravasation rate: 12.75% compared to 2.94% and to 3.43% (
< 0.0001). During Period C and D technologists achieved extravasation rates comparable to the longstanding manual
F-FDG injection extravasation rate (3.4%).
Our initial hypothesis, that awareness of a problem and the steps need to correct it would result in process improvement, was not accurate. While those factors are important, they are not sufficient. Our findings suggest that active monitoring and the associated display of results are critical to quality improvement efforts to reduce and sustain radiopharmaceutical extravasation rates.</description><identifier>ISSN: 2673-8880</identifier><identifier>EISSN: 2673-8880</identifier><identifier>DOI: 10.3389/fnume.2023.1126029</identifier><identifier>PMID: 39355027</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Nuclear Medicine</subject><ispartof>Frontiers in nuclear medicine, 2023-03, Vol.3, p.1126029</ispartof><rights>2023 Crowley, Barvi and Kiser.</rights><rights>2023 Crowley, Barvi and Kiser. 2023 Crowley, Barvi and Kiser</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-a8c54160fc4c03b9a7acd501c4e9f2dcea52777a4a7cb1db9cc991612e9cae3b3</citedby><cites>FETCH-LOGICAL-c403t-a8c54160fc4c03b9a7acd501c4e9f2dcea52777a4a7cb1db9cc991612e9cae3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440977/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440977/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39355027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crowley, James R</creatorcontrib><creatorcontrib>Barvi, Iryna</creatorcontrib><creatorcontrib>Kiser, Jackson W</creatorcontrib><title>Active monitoring improves radiopharmaceutical administration quality</title><title>Frontiers in nuclear medicine</title><addtitle>Front Nucl Med</addtitle><description>In 2016, our center adopted technology to routinely monitor
F-FDG radiopharmaceutical administrations. Within six months of following basic quality improvement methodology, our technologists reduced extravasation rates from 13.3% to 2.9% (
< 0.0001). These same technologists administer other radiopharmaceuticals (without monitoring technology) for general nuclear medicine procedures in a separate facility at the clinic. Our hypothesis was that they would apply
F-FDG lessons-learned to
Tc-MDP administrations and that
Tc-MDP manual injection extravasation rate would be consistent with the ongoing
F-FDG manual injection extravasation rate (3.4%). We tested our hypothesis by following the same quality improvement methodology and added monitoring equipment to measure extravasation rates for
Tc-MDP administrations.
816
Tc-MDP administrations were monitored during 16-month period (four 4-month periods: A, B, C, D). Period A (first four months of active monitoring) extravasation rate was not statistically different from the Measure Phase extravasation rate of the previously completed PET/CT QI Project: 12.75% compared to 13.3% (
-0.7925). Period A extravasation rate was statistically different from Period C (months 9-12) extravasation rate and Period D (months 13-16) extravasation rate: 12.75% compared to 2.94% and to 3.43% (
< 0.0001). During Period C and D technologists achieved extravasation rates comparable to the longstanding manual
F-FDG injection extravasation rate (3.4%).
Our initial hypothesis, that awareness of a problem and the steps need to correct it would result in process improvement, was not accurate. While those factors are important, they are not sufficient. Our findings suggest that active monitoring and the associated display of results are critical to quality improvement efforts to reduce and sustain radiopharmaceutical extravasation rates.</description><subject>Nuclear Medicine</subject><issn>2673-8880</issn><issn>2673-8880</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVUctqwzAQFKWlCWl-oIfiYy9O9bJlnUoI6QMCvbRnsZblRMW2HMkO5O_rNGlIT7vLzswuMwjdEzxjLJNPZdPXZkYxZTNCaIqpvEJjmgoWZ1mGry_6EZqG8I0xpiLjFPNbNGKSJckwj9Fyrju7M1HtGts5b5t1ZOvWu50JkYfCunYDvgZt-s5qqCIoatvY0HnorGuibQ-V7fZ36KaEKpjpqU7Q18vyc_EWrz5e3xfzVaw5Zl0MmU44SXGpucYslyBAFwkmmhtZ0kIbSKgQAjgInZMil1pLSVJCjdRgWM4m6Pmo2_Z5bQZCMzxSqdbbGvxeObDq_6axG7V2O0UI51gKMSg8nhS82_YmdKq2QZuqgsa4Pig2mElIKhM5QOkRqr0LwZvyfIdgdchA_WagDhmoUwYD6eHywzPlz3H2A30FhuY</recordid><startdate>20230307</startdate><enddate>20230307</enddate><creator>Crowley, James R</creator><creator>Barvi, Iryna</creator><creator>Kiser, Jackson W</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230307</creationdate><title>Active monitoring improves radiopharmaceutical administration quality</title><author>Crowley, James R ; Barvi, Iryna ; Kiser, Jackson W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-a8c54160fc4c03b9a7acd501c4e9f2dcea52777a4a7cb1db9cc991612e9cae3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Nuclear Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crowley, James R</creatorcontrib><creatorcontrib>Barvi, Iryna</creatorcontrib><creatorcontrib>Kiser, Jackson W</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Frontiers in nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crowley, James R</au><au>Barvi, Iryna</au><au>Kiser, Jackson W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Active monitoring improves radiopharmaceutical administration quality</atitle><jtitle>Frontiers in nuclear medicine</jtitle><addtitle>Front Nucl Med</addtitle><date>2023-03-07</date><risdate>2023</risdate><volume>3</volume><spage>1126029</spage><pages>1126029-</pages><issn>2673-8880</issn><eissn>2673-8880</eissn><abstract>In 2016, our center adopted technology to routinely monitor
F-FDG radiopharmaceutical administrations. Within six months of following basic quality improvement methodology, our technologists reduced extravasation rates from 13.3% to 2.9% (
< 0.0001). These same technologists administer other radiopharmaceuticals (without monitoring technology) for general nuclear medicine procedures in a separate facility at the clinic. Our hypothesis was that they would apply
F-FDG lessons-learned to
Tc-MDP administrations and that
Tc-MDP manual injection extravasation rate would be consistent with the ongoing
F-FDG manual injection extravasation rate (3.4%). We tested our hypothesis by following the same quality improvement methodology and added monitoring equipment to measure extravasation rates for
Tc-MDP administrations.
816
Tc-MDP administrations were monitored during 16-month period (four 4-month periods: A, B, C, D). Period A (first four months of active monitoring) extravasation rate was not statistically different from the Measure Phase extravasation rate of the previously completed PET/CT QI Project: 12.75% compared to 13.3% (
-0.7925). Period A extravasation rate was statistically different from Period C (months 9-12) extravasation rate and Period D (months 13-16) extravasation rate: 12.75% compared to 2.94% and to 3.43% (
< 0.0001). During Period C and D technologists achieved extravasation rates comparable to the longstanding manual
F-FDG injection extravasation rate (3.4%).
Our initial hypothesis, that awareness of a problem and the steps need to correct it would result in process improvement, was not accurate. While those factors are important, they are not sufficient. Our findings suggest that active monitoring and the associated display of results are critical to quality improvement efforts to reduce and sustain radiopharmaceutical extravasation rates.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>39355027</pmid><doi>10.3389/fnume.2023.1126029</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2673-8880 |
| ispartof | Frontiers in nuclear medicine, 2023-03, Vol.3, p.1126029 |
| issn | 2673-8880 2673-8880 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11440977 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Nuclear Medicine |
| title | Active monitoring improves radiopharmaceutical administration quality |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A04%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Active%20monitoring%20improves%20radiopharmaceutical%20administration%20quality&rft.jtitle=Frontiers%20in%20nuclear%20medicine&rft.au=Crowley,%20James%20R&rft.date=2023-03-07&rft.volume=3&rft.spage=1126029&rft.pages=1126029-&rft.issn=2673-8880&rft.eissn=2673-8880&rft_id=info:doi/10.3389/fnume.2023.1126029&rft_dat=%3Cproquest_pubme%3E3112116959%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3112116959&rft_id=info:pmid/39355027&rfr_iscdi=true |